Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

Methods study to evaluate use of cardiac ultrasound to assess heart valve abnormality in people.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Valve Diseases Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer Investigational Site

New Haven, Connecticut, 06511-5473, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

>=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion criteria

Pregnant females
Those with unstable/new onset diseases
Those who are on agents known to be associated with cardiac valvular heart disease

Treatment and study plan

cardiac echosonography

Device

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects

Important dates

Study start: 2007
Study completion: 2007
First posted: Aug 2, 2006
Registry last updated: Sep 17, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed